ATE382044T1 - Imidazol- derivate - Google Patents

Imidazol- derivate

Info

Publication number
ATE382044T1
ATE382044T1 AT00978816T AT00978816T ATE382044T1 AT E382044 T1 ATE382044 T1 AT E382044T1 AT 00978816 T AT00978816 T AT 00978816T AT 00978816 T AT00978816 T AT 00978816T AT E382044 T1 ATE382044 T1 AT E382044T1
Authority
AT
Austria
Prior art keywords
imidazole derivatives
occurred
excessive
inappropriate
mammal
Prior art date
Application number
AT00978816T
Other languages
English (en)
Inventor
Jerry Adams
Neil Johnson
Jeffrey Murray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE382044T1 publication Critical patent/ATE382044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
AT00978816T 1999-11-22 2000-11-20 Imidazol- derivate ATE382044T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16688599P 1999-11-22 1999-11-22
US16689599P 1999-11-22 1999-11-22
US16681499P 1999-11-22 1999-11-22
US16688699P 1999-11-22 1999-11-22

Publications (1)

Publication Number Publication Date
ATE382044T1 true ATE382044T1 (de) 2008-01-15

Family

ID=27496721

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00977660T ATE281451T1 (de) 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren
AT00978816T ATE382044T1 (de) 1999-11-22 2000-11-20 Imidazol- derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00977660T ATE281451T1 (de) 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren

Country Status (21)

Country Link
US (3) US7189745B1 (de)
EP (2) EP1232153B1 (de)
JP (2) JP2003514906A (de)
KR (1) KR20020050294A (de)
CN (1) CN1543346A (de)
AT (2) ATE281451T1 (de)
AU (2) AU1529901A (de)
BR (1) BR0015532A (de)
CA (1) CA2395564A1 (de)
CZ (1) CZ20021746A3 (de)
DE (2) DE60037597T2 (de)
ES (2) ES2298165T3 (de)
HK (1) HK1050190A1 (de)
HU (1) HUP0203403A3 (de)
IL (2) IL149150A0 (de)
MX (1) MXPA02005106A (de)
NO (1) NO20022318D0 (de)
NZ (1) NZ518032A (de)
PL (1) PL355912A1 (de)
TR (1) TR200201364T2 (de)
WO (2) WO2001037835A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
BR0015532A (pt) 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
ATE365730T1 (de) 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1423383B1 (de) * 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf-kinase inhibitoren
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
JP2005538118A (ja) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Ｔｉｅ２（ｔｅｋ）活性を持つ縮合したピリジン及びピリミジン
EP1539121A4 (de) 2002-08-29 2008-08-13 Scios Inc Verfahren zur forderung der osteogenese
BR0315580A (pt) * 2002-10-24 2005-08-30 Merck Patent Gmbh Derivados de metileno uréia
EP2426122A1 (de) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylenharnstoffderivate als Inhibitoren von RAF Kinase
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1581222A2 (de) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. Zusammensetzung und verfahren zur tgf-b inhibierung
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7569593B2 (en) 2003-10-02 2009-08-04 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20090253688A1 (en) * 2004-02-26 2009-10-08 Merck Patent Gmbh Semicarbazide derivatives as kinase inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
US7807832B2 (en) 2005-07-28 2010-10-05 Janssen Pharmaceutica Nv Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
AR056556A1 (es) 2005-09-30 2007-10-10 Astrazeneca Ab Imidazo(1,2-a)piridina con actividad antiproliferacion celular
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2021338A1 (de) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylaminosäurederivate und pharmazeutische zusammensetzung davon
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
EA201001456A1 (ru) * 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
BR112012008271A2 (pt) * 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
RS59181B1 (sr) * 2009-10-16 2019-10-31 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
WO2011077387A1 (en) * 2009-12-22 2011-06-30 Csir Inhibition of the activity of kinase and synthetase enzymes
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
BR112019005046A2 (pt) 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
US10605785B2 (en) * 2017-06-07 2020-03-31 General Electric Company Sensor system and method

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4447413A (en) * 1980-05-08 1984-05-08 Aviation Chemical, Inc. Drift influencing composition
US4348404A (en) 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
GR75287B (de) 1980-07-25 1984-07-13 Ciba Geigy Ag
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
DE69401486T2 (de) 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0889887A4 (de) 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
DE69729946T2 (de) 1996-10-15 2005-01-20 G.D. Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
WO1998056788A1 (en) 1997-06-12 1998-12-17 Rhone-Poulenc Rorer Limited Imidazolyl-cyclic acetals
IL133766A0 (en) 1997-06-30 2001-04-30 Ortho Mcneil Pharm Inc 2-substituted imidazoles useful in the treatment of inflammatory diseases
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
DE1049664T1 (de) 1997-12-22 2001-05-03 Bayer Ag Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
TR200002617T2 (tr) * 1997-12-22 2000-11-21 Bayer Corporation Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
CN1302296A (zh) * 1998-05-22 2001-07-04 史密丝克莱恩比彻姆公司 新的2－烷基取代咪唑化合物
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AU6476599A (en) * 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
WO2000034255A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
JP2002542280A (ja) 1999-04-27 2002-12-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な治療
BR0015532A (pt) 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
DE60112312T2 (de) 2000-09-21 2005-12-29 Smithkline Beecham P.L.C., Brentford Imidazolderivate als raf-kinase-inhibitoren
ATE365730T1 (de) 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
EP1423383B1 (de) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf-kinase inhibitoren
WO2003022837A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors

Also Published As

Publication number Publication date
KR20020050294A (ko) 2002-06-26
AU1529901A (en) 2001-06-04
US7026336B1 (en) 2006-04-11
PL355912A1 (en) 2004-05-31
HUP0203403A3 (en) 2004-01-28
JP2003514860A (ja) 2003-04-22
US20070010534A1 (en) 2007-01-11
NO20022318L (no) 2002-05-15
MXPA02005106A (es) 2002-11-07
NZ518032A (en) 2004-02-27
EP1233769A4 (de) 2004-12-29
US7189745B1 (en) 2007-03-13
CA2395564A1 (en) 2001-05-31
HK1050190A1 (zh) 2003-06-13
EP1233769A1 (de) 2002-08-28
EP1232153B1 (de) 2004-11-03
WO2001038324A3 (en) 2002-05-10
EP1232153A2 (de) 2002-08-21
TR200201364T2 (tr) 2002-10-21
AU1623601A (en) 2001-06-04
ES2228629T3 (es) 2005-04-16
ATE281451T1 (de) 2004-11-15
WO2001037835A1 (en) 2001-05-31
ES2298165T3 (es) 2008-05-16
DE60037597D1 (de) 2008-02-07
JP2003514906A (ja) 2003-04-22
CZ20021746A3 (cs) 2002-10-16
DE60037597T2 (de) 2008-12-11
DE60015594T2 (de) 2005-10-27
BR0015532A (pt) 2002-06-25
HUP0203403A2 (hu) 2003-02-28
IL149150A (en) 2007-02-11
IL149150A0 (en) 2002-12-01
DE60015594D1 (de) 2004-12-09
CN1543346A (zh) 2004-11-03
WO2001038324A2 (en) 2001-05-31
EP1233769B1 (de) 2007-12-26
NO20022318D0 (no) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE382044T1 (de) Imidazol- derivate
DE60129154D1 (de) Neuartige verbindungen
ATE301651T1 (de) Substituierte benzimidazole
IS6617A (is) Melanókortín viðtakabindlar
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
NZ513096A (en) Compositions for treating inflammatory response
ES2184097T3 (es) Nuevos compuestos.
TR199500956A2 (tr) Benzimidazol türevleri.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
EP1372648A4 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
CO5180558A1 (es) Derivados de n-[3-((piperidin-1-il)metil)-4-(fenil o hetero- ciclil)ciclopent-1-il]]amina utiles como moduladores de actividad del receptor de la quimioquina
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
PL356931A1 (en) Use of natural compounds having antiangiogenic activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties